Literature DB >> 4014250

Controlling cephalosporin and aminoglycoside costs through pharmacy and therapeutics committee restrictions.

J N Hayman, E C Sbravati.   

Abstract

The cost-reducing effect of antibiotic restrictions imposed by a pharmacy and therapeutics (P & T) committee was evaluated. The pharmacy department developed guidelines restricting the use of second-generation cephalosporins and aminoglycosides in cooperation with the infectious disease division. The P & T committee approved the restrictions, and the pharmacy department disseminated information on the program to the hospital's physicians. Specific indications were developed for the use of amikacin, tobramycin, cefoxitin, and cefamandole. In order to prescribe a restricted antibiotic, physicians are required to write an approved indication on the physician's order form. Residents cannot prescribe restricted antibiotics for unapproved indications unless they acquire the signature of an attending physician. Pharmacy personnel closely monitor the restricted antibiotic use and enforce the established guidelines. The major impact of the restrictions was the reversal of a previous trend toward the use of more expensive second-generation cephalosporins and tobramycin to the use of first-generation cephalosporins and gentamicin. Injectable antibiotic expenses decreased by $193,172 in the first 12 months of the program. Antibiotic restrictions imposed by the P & T committee were effective in reducing the cost of antimicrobial therapy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4014250

Source DB:  PubMed          Journal:  Am J Hosp Pharm        ISSN: 0002-9289


  11 in total

1.  Antimicrobial stewardship.

Authors:  Shira Doron; Lisa E Davidson
Journal:  Mayo Clin Proc       Date:  2011-11       Impact factor: 7.616

Review 2.  Economic impact of cost-containment strategies in third party programmes in the US. Part II.

Authors:  C M Kozma; R M Schulz; W M Dickson; J T Dye; E R Cox; D A Holdford; L Michael; W N Yates; T L Young
Journal:  Pharmacoeconomics       Date:  1993-09       Impact factor: 4.981

3.  Using cost of infection as a tool to demonstrate a difference in prophylactic antibiotic efficacy: a prospective randomized comparison of the pharmacoeconomic effectiveness of ceftriaxone and cefotaxime prophylaxis in abdominal surgery.

Authors:  John C Woodfield; Andre M Van Rij; Ross A Pettigrew; Antje van der Linden; Donna Bolt
Journal:  World J Surg       Date:  2005-01       Impact factor: 3.352

Review 4.  Methods of minimising the cost of aminoglycoside therapy to hospitals.

Authors:  C A Gentry; K A Rodvold; J S Bertino
Journal:  Pharmacoeconomics       Date:  1993-03       Impact factor: 4.981

Review 5.  Antimicrobial therapy. Cost-benefit considerations.

Authors:  B J Guglielmo; G F Brooks
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

6.  Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases.

Authors:  K de With; F Allerberger; S Amann; P Apfalter; H-R Brodt; T Eckmanns; M Fellhauer; H K Geiss; O Janata; R Krause; S Lemmen; E Meyer; H Mittermayer; U Porsche; E Presterl; S Reuter; B Sinha; R Strauß; A Wechsler-Fördös; C Wenisch; W V Kern
Journal:  Infection       Date:  2016-06       Impact factor: 3.553

Review 7.  The role of the infectious diseases physician in monitoring antimicrobial use: a pharmacy perspective.

Authors:  R E Polk
Journal:  Bull N Y Acad Med       Date:  1987 Jul-Aug

8.  Implementation and evaluation of a preprinted perioperative antimicrobial prophylaxis order form in a teaching hospital.

Authors:  P Au; S Salama; C Rotstein
Journal:  Can J Infect Dis       Date:  1998-05

Review 9.  Cephalosporin utilisation review and evaluation.

Authors:  G M Misan; C Dollman; D R Shaw; N Burgess
Journal:  Pharmacoeconomics       Date:  1995-08       Impact factor: 4.981

Review 10.  Cost considerations in therapeutic drug monitoring of aminoglycosides.

Authors:  J S Bertino; K A Rodvold; C J Destache
Journal:  Clin Pharmacokinet       Date:  1994-01       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.